MAKE PROTECTION YOUR SUPERPOWER
Protect your patients who have cardio, renal, and metabolic conditions.
Shorts
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Subodh Verma (Canada)
Why should empagliflozin be your first choice in heart failure management?
Subodh Verma (Canada)
Benefits of starting an SGLT2 inhibitor upon clinical diagnosis of heart failure
Upcoming Events
Heart Failure 360: Early protection for every heart failure patient
Past Events
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2)
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1)
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Full; Day 2)
Resources
Patient Materials
PDF